The link between dopamine, prolactin and male sexuality

Dostinex is one of the most effective oral drugs whose action is aimed at reducing the secretion of the hormone prolactin contained in human blood in several forms. The endocrine system is responsible for the activity of biologically active substances. Hormones affect all processes in the human body, and any hormonal imbalance leads to a failure in the activity of all its systems.

In healthy individuals, prolactin is regulated and stabilized at normal (low) levels with the help of neurotransmitter known as dopamine. Dopamine is a chemical engaged in the so called reward system stimulating the brain’s pleasure center; by association, it is also responsible for the formation of addictive behaviors.

Dostinex has a close affinity to dopamine; it is called dopamine agonist, since its action fully mimics that of dopamine, including prolactin inhibition and regulation of compulsive behaviors associated with pleasure center of the brain, but also sexual behavior. The hormone prolactin is released after ejaculation to conversely influence the effects caused by dopamine and initiate the process of relaxation. In individuals with hyperprolactinemia conditions (excessive secretion of prolactin) this hormone interferes with sexual function on all levels, neuropsychic (arousal, sexual drive, sexual stamina) and organic (erectile mechanism, ejaculation and orgasm).

The name of Dostinex is often linked to sexual function and sexual gratification in specific literature. The drug suppresses the production of prolactin and reduces pressure. In addition and based on its powerful dopaminergic potential, Dostinex is used to address the lack of libido, compromised erectile function and male orgasmic disorder.

Orgasmic disorders in males

The male orgasm normally coincides with ejaculation. When orgasm is reached, in fact, in man there is the sensation of inevitability of ejaculation, followed by sperm emission. The male descriptions of the orgasm are less precise than the female ones; this suggests, therefore, that men have less knowledge of their anatomy or more simply are more reticent in describing their feelings.

In the disorder of the male orgasm, the response to sexual stimulation and the maintenance of an erection are good, but orgasm is not achieved. While experiencing the urgent desire of the orgasmic discharge and receiving sufficient stimulation to provoke it, in the presence of this disorder, man fails to trigger the orgasmic reflex. Generally, anorgasmia (absence of orgasm) occurs in coitus, but not during masturbation or other sources of stimulation.

The difficulty of full sexual intercourse creates a strong frustration and performance anxiety, since sexual efficiency is one of the elements that contribute to the construction of a satisfying self-image. The presence of performance anxiety significantly complicates the spontaneous resolution of the problem, consolidating and multiplying the experiences of failure. A disorder, which could perhaps only be occasional, can thus become recurrent, requiring at this point the intervention of the psychotherapist.

A recent study in elderly and middle-aged men confirms the correlation between low levels of prolactin (PRL) and sexual, psychological and metabolic disorders. Previous studies have shown that, in a large male population, reduced prolactin concentrations were associated with anxiety, sexual symptoms (orgasm disorder and erectile dysfunction), worsening of the lipid and glycemic profile, metabolic syndrome and increase in major cardiovascular adverse events .

The aim of this study was to evaluate the correlation between low levels of prolactin and the clinical, psychological and sexual aspects in a large non-hospitalized male population (age 40-79) enrolled in the European Male Aging Study (EMAS) study prospective, observational, conducted in 8 European centers. The 2,948 participants, randomized in 4 age groups (40-49, 50-59, 60-69 and 70-79 years), before being subjected to medical examination, had to provide some personal information (health status, type of employment, education, cigarette smoking, alcohol consumption, comorbidity) by filling in specific questionnaires sent by mail.

The results confirmed the association between variation in sexual function and low levels of prolactin, especially regarding the reduction in pleasure that accompanies orgasm compared to the previous year.

An inverse relationship between PRL levels and number of adverse events, depressive symptoms, physical activity and metabolic syndrome was also observed.

Overall, the results of this study indicate that the control of prolactinemia in male subjects can provide information about their metabolic, psychological and sexual characteristics; moreover it can be useful to stratify this population according to the cardiovascular risk and to stimulate appropriate variations in the lifestyle.

However, further studies are needed to understand whether “hypoprolactinemic” subjects may require pharmacological intervention.

Is Dostinex approved for male orgasmic disorder?

There is little evidence in the literature that demonstrates the effectiveness of medical therapy in the management of male orgasmic disorders. Although the Food and Drug Association (FDA) does not approve the use of off-label drugs for the treatment of male orgasmic disorder, some studies in the literature have shown a discreet success of the therapy with antiserum tonic agents (cyproheptadine) and dopamine agonists (cabergoline) in patients who already took the serotonin reuptake inhibitors (SSRIs). However, these data must be considered as preliminary, given the limits of the studies themselves, based on small ones samples not compared with control groups.

However, used as a part of a complex therapy course aimed at lowering prolactin levels in subjects with prolactinoma and other conditions associated with hyperprolactinemia states, Dostinex is reported to have the following effects on male sexuality:

  • restored erectile ability
  • harder, more controllable erection
  • increased control over IVLT (intravaginal latency time)
  • increased sexual drive (libido)
  • augmented sexual endurance (stamina)
  • shortened recovery time between sexual acts
  • restored orgasmic mechanism
  • restored ejaculation mechanism

Remember that medical prescription is required to initiate Dostinex therapy, and regular monitoring of blood prolactin levels during the entire therapy course which may last for several months, and sometimes for a lifetime, in order to achieve and sustain meaningful health results.